THE CANADIAN HEALTHY INFANT LONGITUDINAL DEVELOPMENT (CHILD) STUDY

How 3,500 Canadian children are helping us find ways to prevent asthma, allergies, obesity and other chronic diseases



A novel platform—unique in the world—to predict, prevent and treat disease.

The CHILD Study is a globally leading birth cohort study that is following **3,500 Canadian children** and their families from pre-birth to school age and beyond.

- an unprecedented pool of early-life human genetics, epigenetics and microbiome data: 600,000 biological samples and 500,000 questionnaire responses spanning genetics, epigenetics, environmental exposures, stress, nutrition and lifestyle
- CHILD is answering questions about the origins of chronic diseases and identifying early life "critical windows" that will build healthier futures
 - o an extraordinary opportunity to study **children's health** and the development of asthma, allergies, obesity, diabetes, and cardiovascular diseases over the life course
 - maternal-child health impact areas focus on conditions linked to high morbidity such as neurodevelopment and mental health

Mobilizing knowledge from CHILD	
Peer-reviewed publications	25
Abstracts (national and international)	150
Media stories featuring the CHILD Study	675

CHILD Study Platform Investors		
AllerGen	\$13,270,000	
CIHR	\$21,469,199	
Federal (other)	\$2,871,875	
Provincial	\$1,558,730	
Industry	\$442,000	
TOTAL since 2005	\$39,611,804	

A pan-Canadian effort with a global reputation.

- a **national effort** involving four provinces (British Columbia, Alberta, Manitoba, Ontario), 30 Canadian researchers/scientists, plus 45 research trainees at 11 universities and hospitals
- positioning Canadians as global leaders in the Developmental Origins of Health and Disease (DOHaD)
- a critical platform integral to other scientific studies and new diagnostics and treatments
 - 41 research grants valued at more than \$39M have been/are dependent on the CHILD Study's expertise, samples and data
 - related patent filings at The University of British Columbia and the University of Alberta are contributing to the commercialization of novel therapies emerging from CHILD research





Breakthrough scientific findings generating worldwide attention:



Science Translational Medicine BBC, Fox News, Washington Post



Environmental Health Perspectives

CBC, Vancouver Sun,

Toronto Sun



EBioMedicine
CTV News, Global News



JAMA Pediatrics **LA Times, TIME, CBS**



Clinical & Experimental Allergy
CTV, Toronto Star



BJOG: An International Journal of Obstetrics and Gynaecology Macleans



Jrl of Exposure Science and Environmental Epidemiology



Can. Medical Association Jrl TIME, New York Times, Globe & Mail

Why continue to build on CIHR's investment in the CHILD Study?

By 2018, the CHILD Study will inform decisions on:

- healthy homes and communities
- relationship between prenatal and infant nutrition on infant food allergy
- role of viruses and genetics on lung health
- links between immune development and infant microbiome, host genetics, allergies, eczema, prenatal psychosocial and demographic factors
- impact of food, allergen and mould exposures on wheeze, dermatitis and asthma
- impact of phthalate exposure in early life on the development of allergic disease
- role of sleep on obesity and neurodevelopment
- link between psychosocial factors and asthma outcomes

Award-winning CHILD Study video

0 4,000 views in 88 countries



